A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy.
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Brivaracetam (Primary) ; Brivaracetam (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors UCB
- 05 Dec 2017 Results of pooled analysis from two phase II, six phase III and associated long-term follow-up studies presented at the 71st Annual Meeting of the American Epilepsy Society.
- 25 May 2016 Results published in the Epilepsia
- 10 Dec 2013 Results presented at the 67th Annual Meeting of the American Epilepsy Society.